BIOSTEM TECHNOLOGIES (BSEM) Company Report

Analyst Coverage

Research analysts who have asked questions during BIOSTEM TECHNOLOGIES earnings calls.

Erik Voss

Mission Vertical

2 questions for BSEM

Bradley Sorensen

Analyst

1 question for BSEM

Bruce Jackson

The Benchmark Company LLC

1 question for BSEM

Also covers: BFRI, BLTE, CV +8 more

Ernest Watts

Watts Associates

1 question for BSEM

Kevin

RBC Capital Markets

1 question for BSEM

Also covers: ARBK, CMPS, GHG +3 more

Kevin Peterson

Petersen Capital

1 question for BSEM

Mitchell Sacks

Grand Slam

1 question for BSEM

Page Taggart

APT Capital

1 question for BSEM

Paige Taggart

APT Consulting

1 question for BSEM

Peter Stoddard

Stoddard Investments

1 question for BSEM

Swayampakula Ramakanth

H.C. Wainwright & Co.

1 question for BSEM

Also covers: ABSI, CGEN, CLGN +26 more

Latest news

Recent press releases and 8-K filings for BSEM.

BioStem Technologies Discusses Strategic Growth, BioTissue Acquisition Impact, and 2026 Reimbursement Changes

BSEM

M&A

Product Launch

Revenue Acceleration/Inflection

BioStem Technologies has significantly diversified its portfolio and market reach through the recent acquisition of BioTissue's surgical and wound care assets, which include the Neox and Clarix product families and expand the company into surgical settings, OR-based procedures, and hospital channels.
The acquired BioTissue surgical and wound care assets generated approximately $29 million in revenue in 2025 with a single-digit positive EBITDA.
The company anticipates a "rocky" first half of 2026 in the physician office segment due to new Medicare reimbursement changes, but views the new fixed-rate reimbursement model for hospital outpatient and ambulatory surgery centers (ASC) as an opportunity to treat larger wounds.
BioStem is expanding its commercial team with 18 direct sales representatives and 32 independent sales agents from the BioTissue acquisition, and expects a 510(k) product in the middle to back half of 2026 to further diversify into orthopedics and other use cases.
The company is actively pursuing an uplisting process, with KPMG expected to complete the 2024 and 2025 audits by the end of Q1 2026.

Mar 2, 2026, 8:50 PM

Transcript

BioStem Technologies Discusses BioTissue Acquisition, 2025 Revenue, and 2026 Outlook

BSEM

M&A

Guidance Update

Product Launch

BioStem Technologies acquired BioTissue surgical and wound care assets, which generated approximately $29 million in surgical revenue in 2025 and diversified the company's portfolio into new market segments, including orthopedics, urology, and women's health.
The company expects a 510(k) product clearance in the middle to back half of 2026, with a $10 million milestone payment tied to its approval.
BioStem financed the initial tranche of the BioTissue acquisition with its own cash, retaining approximately $16 million in cash on its balance sheet.
The company anticipates a "rocky" first half of 2026 in the physician office segment due to new Medicare reimbursement changes for 2026, which include a fixed rate of $127 per square centimeter plus an application fee.
BioStem is pursuing a Nasdaq up-list, with KPMG completing the 2024 and 2025 audits by the end of Q1 2026.

Mar 2, 2026, 8:50 PM

Transcript

BioStem Technologies Discusses Strategic Growth and Financial Outlook at TD Cowen Conference

BSEM

M&A

Guidance Update

New Projects/Investments

BioStem Technologies highlighted its recent acquisition of BioTissue's surgical and wound care assets, which generated approximately $29 million in surgical revenue in 2025 and expanded its technology platform, product portfolio (Neox and Clarix families), and sales force. This acquisition diversified the company's addressable market to over $23 billion across six core segments.
The company discussed significant changes in Medicare reimbursement for 2026, shifting from bundled rates to a fixed rate of $127 per square centimeter plus an application fee in hospital outpatient settings and $1.27 per square centimeter with a $400 application fee in ASCs. While the first half of 2026 is anticipated to be "rocky" in the physician office segment due to these changes, the new structure allows for treating larger wounds in HOPD/ASC settings.
BioStem reported having $16 million in cash on its balance sheet after financing the initial tranche of the BioTissue acquisition. The company is also progressing towards an up-listing, with KPMG expected to complete the 2024 and 2025 audits by the end of Q1 2026.
Future growth initiatives include the anticipated launch of a 510(k) product in mid-2026 for orthopedic and other use cases, continued investment in its commercial team of 18 direct sales representatives and 32 independent sales agents, and leveraging GPO agreements.

Mar 2, 2026, 8:50 PM

Transcript

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

BSEM

M&A

New Projects/Investments

Revenue Acceleration/Inflection

BioStem Technologies has completed the acquisition of BioTissue Holdings' surgical and wound care business for an upfront cash payment of approximately $15 million, with potential additional regulatory milestone payments of up to $10 million and royalty milestone payments of up to $15 million.
This acquisition doubles BioStem's addressable market by accelerating its entry into the acute wound care market, diversifying end markets, and expanding its product portfolio with brands like NEOX and Claryx.
The acquired assets generated approximately $29 million in 2025 revenue with industry-standard 65% gross margins and are expected to be growth and EBITDA accretive for BioStem in 2026.
The transaction includes the integration of BioTissue's experienced national sales force, comprising approximately 20 direct sales representatives and more than 30 independent sales agents, along with prominent Group Purchasing Organization (GPO) contracts.
BioStem plans to transition the manufacturing of the acquired products in-house after a minimum of 12 months, which is expected to lead to gross margin expansion.

Jan 22, 2026, 1:00 PM

Transcript

BioStem Technologies Completes Acquisition of BioTissue Holdings' Surgical and Wound Care Business

BSEM

M&A

New Projects/Investments

Revenue Acceleration/Inflection

BioStem Technologies (BSEM) completed the acquisition of BioTissue Holdings' surgical and wound care business, which doubles its addressable market and accelerates its entry into the acute wound care market.
The acquired business generated approximately $29 million in 2025 revenue with 65% gross margins and is projected to be growth and EBITDA accretive for BioStem in 2026.
The transaction involved an upfront cash payment of approximately $15 million, with potential future payments including up to $10 million for 510(k) clearance of a pipeline product and royalty milestones up to $15 million.
Post-closing, BioStem's cash and equivalents balance is approximately $16 million.
The acquisition also integrates BioTissue's national sales force, comprising approximately 20 direct sales representatives and over 30 independent sales agents, and includes prominent Group Purchasing Organization (GPO) contracts.

Jan 22, 2026, 1:00 PM

Transcript

BioStem Technologies Completes Acquisition of BioTissue Holdings' Surgical and Wound Care Business

BSEM

M&A

New Projects/Investments

Revenue Acceleration/Inflection

BioStem Technologies has completed the acquisition of BioTissue Holdings' surgical and wound care business for an upfront cash payment of approximately $15 million.
This acquisition is expected to double BioStem's addressable market by accelerating its entry into the acute wound care market, expanding its product portfolio with the NEOX and Claryx product families, and extending its geographic commercial footprint.
The acquired assets generated approximately $29 million in 2025 revenue with industry-standard gross margins of 65% and are expected to be growth and EBITDA accretive for BioStem in 2026.
The transaction includes the integration of BioTissue's experienced national sales force, comprising approximately 20 direct sales representatives and more than 30 independent sales agents, and prominent group purchasing organization (GPO) contracts.
BioStem's cash and equivalents balance post-closing is approximately $16 million, with the initial $15 million payment funded from cash on hand.

Jan 22, 2026, 1:00 PM

Transcript

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

BSEM

M&A

New Projects/Investments

Product Launch

BioStem Technologies, Inc. (OTC: BSEM) completed the acquisition of BioTissue Holdings, Inc.'s non-ocular Surgical and Wound Care business.
This acquisition grants BioStem exclusive rights to the Neox® and Clarix® product lines.
BioTissue's Surgical sales team and key support staff will integrate into BioStem's commercial organization, while BioTissue will continue to manufacture the acquired products for BioStem.
BioStem's CEO, Jason Matuszewski, noted that BioTissue's strengths complement their existing business, presenting a significant opportunity for investment in commercial execution to drive growth.

Jan 21, 2026, 11:00 PM

Press Release

BioStem Technologies Reports Record Q4 2024 Financial Performance

BSEM

Earnings

Revenue Acceleration/Inflection

Product Launch

Q4 revenue reached $102.9 million, up significantly from $11.5 million in Q4 2023, driving full‑year revenue to $301.8 million with positive GAAP net income, reflecting strong operational execution.
The company achieved robust market impact with the nationwide launch of VENDAJE AC and strong adoption of AmnioWrap2, positioning its clinical trials and strategic initiatives for continued growth in 2025.
BioStem is advancing its strategic initiatives with progress on uplisting to NASDAQ and an improved cash balance of $22.8 million at Q4 end, underpinning its future expansion efforts.